New hope for hard-to-treat esophageal cancer?
NCT ID NCT05022654
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 31 times
Summary
This study tests a combination of two drugs, SI-B001 and irinotecan, in people with advanced esophageal cancer that has come back or spread and no longer responds to standard treatments. The goal is to see if the combo can shrink tumors and how safe it is. About 22 adults aged 18 to 75 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anyang Cancer Hospital of Henan Province
Anyang, Henan, China
-
Beijing Cancer Hostital
Beijing, Beijing Municipality, 100142, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
-
Suining Central Hospital
Suining, Sichuan, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Conditions
Explore the condition pages connected to this study.